What is the average price target for CORTEXYME INC (CRTX) stock?
11 analysts have analysed CRTX and the average price target is 22.7 USD. This implies a price increase of 1063.85% is expected in the next year compared to the current price of 1.95.
CORTEXYME INC (CRTX) Forecast, Price Target & Analyst Ratings
NASDAQ:CRTX • US22053A1079
Current stock price
1.95 USD
+0.05 (+2.63%)
At close:
1.99 USD
+0.04 (+2.05%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CORTEXYME INC (CRTX).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q2 / 2022
- EPS Estimate
- -$0.59
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$22.70
Upside
+ 1,063.85%
From current price of $1.95 to mean target of $22.70, Based on 11 analyst forecasts
Low
$3.03
Median
$8.16
High
$100.80
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
11 Wall Street analysts provided a forecast for the next 12 months for CRTX. The average price target is 22.7 USD. This implies a price increase of 1063.85% is expected in the next year compared to the current price of 1.95.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
45.45%
CRTX was analyzed by 11 analysts. The buy percentage consensus is at 45. So analysts seem to be rather negative about CRTX.
In the previous month the buy percentage consensus was at a similar level.
CRTX was analyzed by 11 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-05-11 | Credit Suisse | Maintains | Underperform |
| 2022-03-09 | HC Wainwright & Co. | Maintains | Buy |
| 2022-01-28 | Canaccord Genuity | Downgrade | Buy -> Hold |
| 2022-01-27 | JMP Securities | Downgrade | Market Outperform -> Market Perform |
| 2021-10-27 | B of A Securities | Downgrade | Neutral -> Underperform |
| 2021-10-27 | HC Wainwright & Co. | Maintains | Buy |
| 2021-09-16 | Canaccord Genuity | Maintains | Buy |
| 2021-08-26 | HC Wainwright & Co. | Maintains | Buy |
| 2021-02-17 | Jefferies | Downgrade | Buy -> Hold |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q2 / 2022
- EPS Estimate
- -$0.59
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 19.71%
- Number of Analysts
- 8
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | ||||||
| EBITDA YoY % growth | -10.32M | -12.07M -16.96% | -38.98M -222.95% | -78.56M -101.54% | -89.974M -14.53% | N/A 24.42% | N/A 11.70% | N/A -9.08% | N/A 0.68% | N/A -1.31% | |
| EBIT YoY % growth | -10.37M | -12.12M -16.88% | -39.17M -223.18% | -78.89M -101.40% | -90.318M -14.49% | N/A 18.32% | N/A 4.24% | N/A -5.45% | N/A 2.55% | N/A 0.60% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | -2.90 | -2.63 9.31% | -3.03 -15.21% | N/A 20.50% | N/A 17.25% | N/A 0.62% | N/A -6.80% | N/A -8.93% |
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q2 / 22 | Q3 / 22 | Q4 / 22 | Q1 / 23 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.59 19.71% | -0.58 21.16% | -0.55 29.55% | -0.32 56.22% |
| Revenue Q2Q % growth | N/A | |||
| EBITDA Q2Q % growth | -21.93M -1.48% | -19.788M 7.61% | -19.39M 16.42% | N/A |
| EBIT Q2Q % growth | -21.93M -0.67% | -19.788M 8.71% | -19.39M 17.64% | N/A |
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
10.42%
EPS Next 5 Year
4.39%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
CORTEXYME INC / CRTX Forecast FAQ
What are the consensus estimates for CORTEXYME INC (CRTX) next earnings?
The consensus EPS estimate for the next earnings of CORTEXYME INC (CRTX) is -0.59 USD and the consensus revenue estimate is 0 USD.